MICHAEL KAPLAN: Open Payments
NPI 1841298593 · SMITHTOWN, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$134,036 in 210 payments from 7 companies in 2025. Trend: 2023 $45,959 · 2024 $83,755 · 2025 $134,036
Speaker / faculty: $120,790Travel & lodging: $6,581Consulting: $4,025Food & beverage: $2,640
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 154 | $87,563 |
| Novo Nordisk Inc | 50 | $46,223 |
| Boston Scientific Corporation | 1 | $148 |
| Corcept Therapeutics | 2 | $36 |
| SOBI, INC | 1 | $30 |
| Ardelyx, Inc. | 1 | $21 |
| Currax Pharmaceuticals LLC | 1 | $15 |
Products named: ZEPBOUND, Wegovy, General - Vascular Intervention, MOUNJARO, Korlym, IBSRELA, CONTRAVE.
Industry payments across NY — which companies pay providers there.
